Recognizing early signs in the translational phase is essential for drug development in cardiovascular medicine.
作者信息
Papp Zoltán, Pollesello Piero, Borbély Attila
机构信息
Department of Cardiology, Division of Clinical Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Content and Communications Function, Orion Pharma, Espoo, Finland.
出版信息
ESC Heart Fail. 2023 Aug;10(4):2147-2149. doi: 10.1002/ehf2.14402. Epub 2023 May 10.
Abstract
摘要
相似文献
1
Recognizing early signs in the translational phase is essential for drug development in cardiovascular medicine.在转化阶段识别早期迹象对于心血管医学的药物开发至关重要。
ESC Heart Fail. 2023 Aug;10(4):2147-2149. doi: 10.1002/ehf2.14402. Epub 2023 May 10.
2
Orphan Drug Development in Cardiovascular Medicine.心血管医学中的罕见病药物研发
Circ Cardiovasc Qual Outcomes. 2020 Jul;13(7):e006509. doi: 10.1161/CIRCOUTCOMES.119.006509. Epub 2020 Jun 19.
3
Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.加强儿科心血管药物研发的建议：多利益相关方智库报告
J Am Heart Assoc. 2018 Feb 10;7(4):e007283. doi: 10.1161/JAHA.117.007283.
4
Resuscitating Cardiovascular Drug Development.复苏心血管药物研发
JAMA Cardiol. 2017 Dec 1;2(12):1295-1296. doi: 10.1001/jamacardio.2017.3756.
5
The Imminent Demise of Cardiovascular Drug Development.心血管药物研发的即将终结。
JAMA Cardiol. 2017 Dec 1;2(12):1293-1294. doi: 10.1001/jamacardio.2017.3753.
6
Challenges in the Development of Novel Cardiovascular Therapies.新型心血管疗法研发中的挑战
Clin Pharmacol Ther. 2017 Aug;102(2):194-196. doi: 10.1002/cpt.703. Epub 2017 Jun 23.
7
Cardiovascular and Hematological Medicine in 2019 - Advances and Insights.2019年心血管与血液医学——进展与见解
Cardiovasc Hematol Agents Med Chem. 2019;17(1):2. doi: 10.2174/187152571701190722113042.
8
Organs-on-chip models for cardiovascular drug development.用于心血管药物研发的芯片器官模型。
Cardiovasc Res. 2021 Nov 1;117(12):e164-e165. doi: 10.1093/cvr/cvab229.
9
Cardiovascular pipeline decline quantified.心血管管道衰退量化。
Nat Rev Drug Discov. 2016 Sep 29;15(10):669. doi: 10.1038/nrd.2016.208.
10
A novel approach for establishing cardiovascular drug efficacy.一种确立心血管药物疗效的新方法。
Nat Rev Drug Discov. 2014 Dec;13(12):942. doi: 10.1038/nrd4090-c2. Epub 2014 Nov 14.
引用本文的文献
1
Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.癌症治疗相关心脏功能障碍临床前模型的最新进展：挑战与展望。欧洲心脏病学会心力衰竭协会（HFA）、欧洲心脏病学会心脏肿瘤学委员会以及欧洲心脏病学会心脏细胞生物学工作组的科学声明。
Eur J Heart Fail. 2025 Jun;27(6):1028-1046. doi: 10.1002/ejhf.3636. Epub 2025 Mar 11.
本文引用的文献
1
Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?治疗急性和晚期心力衰竭的短期疗法——为何临床可用药物如此之少，为何研发中的药物更少？
J Clin Med. 2019 Nov 1;8(11):1834. doi: 10.3390/jcm8111834.
2
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.SGLT2抑制剂在心力衰竭中的前景：糖尿病及其他领域
Curr Treat Options Cardiovasc Med. 2017 Mar;19(3):23. doi: 10.1007/s11936-017-0522-x.
3
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.奥马曲拉治疗急性心力衰竭增加收缩力：ATOMIC-AHF 研究。
J Am Coll Cardiol. 2016 Mar 29;67(12):1444-1455. doi: 10.1016/j.jacc.2016.01.031.
4
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data.基于个体患者数据的急性心肌梗死患者细胞心肌研究的荟萃分析（ACCRUE）
Circ Res. 2015 Apr 10;116(8):1346-60. doi: 10.1161/CIRCRESAHA.116.304346. Epub 2015 Feb 19.
5
Drug discovery and development for acute heart failure drugs: are expectations too high?
Int J Cardiol. 2014 Mar 1;172(1):11-3. doi: 10.1016/j.ijcard.2013.12.136. Epub 2014 Jan 4.
6
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.心肌肌球蛋白激活剂奥马环素甲磺酸盐对收缩性心力衰竭患者心功能的影响：一项双盲、安慰剂对照、交叉、剂量范围的 2 期临床试验。
Lancet. 2011 Aug 20;378(9792):676-83. doi: 10.1016/S0140-6736(11)61126-4.
7
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.心肌球蛋白激活：一种治疗收缩性心力衰竭的潜在方法。
Science. 2011 Mar 18;331(6023):1439-43. doi: 10.1126/science.1200113.
8
Assessment and optimization of cell engraftment after transplantation into the heart.移植入心脏后细胞定植的评估和优化。
Circ Res. 2010 Feb 19;106(3):479-94. doi: 10.1161/CIRCRESAHA.109.208991.
9
Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.家族性肾性糖尿和 SGLT2：从孟德尔性状到治疗靶点。
Clin J Am Soc Nephrol. 2010 Jan;5(1):133-41. doi: 10.2215/CJN.04010609. Epub 2009 Nov 5.
10
Calcium sensitivity enhancers.钙敏感性增强剂
IDrugs. 2000 Oct;3(10):1199-205.
Zotero 插件